Fused imidazo-piperidine jak inhibitor compound
AssigneeTheravance Biopharma R&D IP, LLC
InventorsROBERT MURRAY MCKINNELL, VENKAT R. THALLADI, HAO ZHANG, PAUL R. FATHEREE, LAN JIANG, MARTA DABROS, JERRY NZEREM
Life of this patent
Estimating the term…
Abstract
The invention provides a compound of formula 1 or a pharmaceutically-acceptable salt thereof, that is useful as a JAK inhibitor. The invention also provides crystalline forms of the compound, pharmaceutical compositions comprising the compound, methods of using the compound to treat diseases amenable to a JAK inhibitor, and processes and intermediates useful for preparing the compound.
Claims29
1-23. (canceled)
A method of treating an ocular disease in a mammal, the method comprising administering a pharmaceutical composition comprising a compound of formula:
- or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier to the eye of the mammal.
27-31. (canceled)
A method of treating an ocular disease in a mammal, the method comprising administering to the eye of the mammal a pharmaceutical composition comprising a crystalline form of the compound of formula:
- wherein the crystalline form is characterized by a powder X-ray diffraction pattern comprising diffraction peaks at 2θ values of 10.61±0.20, 11.84±0.20, 14.94±0.20, 18.26±0.20, and 19.06±0.20, and a pharmaceutically-acceptable carrier.
A method of treating an ocular disease in a mammal, the method comprising administering to the eye of the mammal a pharmaceutical composition comprising a crystalline form of the compound of formula:
- wherein the crystalline form is characterized by a powder X-ray diffraction pattern comprising diffraction peaks at 2θ values of 8.16±0.20, 8.97±0.20, 15.29±0.20, 16.70±0.20, 18.00±0.20, and 20.18±0.20, and a pharmaceutically-acceptable carrier.
Dependencies are inferred from the claim text.